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Abstract: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, 
affecting 1% to 2% of people older than 60 years. Treatment of PD consists of symptomatic 
therapies while neuroprotective strategies have remained elusive. Rasagiline is a novel, potent, 
and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for 
treatment of PD. Rasagiline inhibits MAO-B more potently than selegiline and has the advan-
tage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has 
demonstrated efficacy as monotherapy in early PD and as adjunctive therapy in advanced PD. 
In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo 
studies. The recently completed delayed-start ADAGIO (Attenuation of Disease Progression 
with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 
1 mg/day, though the clinical import of this finding has yet to be established.
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Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disorder manifested by 
the cardinal features of tremor at rest, rigidity, bradykinesia, and loss of postural 
reflexes. In addition to motor symptoms, PD is associated with a host of non-motor 
symptoms including autonomic disturbance, sleep disorders, depression, psychosis, 
and dementia. The mean age of onset of PD is 60 years and both the prevalence and 
incidence increase with age, with 1% to 2% of the population over age 60 years affected 
by the disease.1 The primary pathology of PD is the degeneration of dopaminergic 
neurons in the substantia nigra pars compacta (SNpc) with subsequent depletion of 
nigrostriatal dopamine, and the development of Lewy bodies, proteinaceous intra-
cytoplasmic inclusions. Recent studies have shown that PD is also associated with 
extensive non-dopaminergic pathology involving noradrenergic neurons in the locus 
coeruleus, cholinergic neurons in the nucleus basalis of Meynert, serotonergic neurons 
in the midline raphe, and neurons of the autonomic nervous system.2 The seminal 
work of Braak et al has demonstrated that the pathological changes in PD occur in 
a relatively predictable, topographically distinct sequence of events beginning with 
the olfactory structures and medulla oblongata, spreading to the substantia nigra, and 
eventually affecting neocortical structures.3
Though the exact pathogenetic mechanisms leading to cell death in PD are not 
fully understood, a number of factors including mitochondrial dysfunction, oxidative 
stress, excitotoxicity, dysfunction of the ubiquitin-proteosome pathway, and apoptosis 
have been implicated.4–6 In 5% to 10% of patients with PD, there is a familial pattern 
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of inheritance and, to date, linkage to 11 different genes has 
been reported.7,8 However, most gene mutations observed in 
PD kindreds do not appear to account for the vast majority 
of PD patients who develop PD sporadically.9 One exception 
is LRRK2 mutations which appear to occur in 41% of North 
African Arabs with sporadic PD and 13.3% of Ashkenazi 
Jews with sporadic PD.10,11 Epidemiologic studies have 
found associations between a variety of environmental agents 
(pesticides, herbicides, rural living) and risk of PD but none 
of these agents has been shown to definitively cause PD.12 
Thus, the cause of the large majority of cases of sporadic PD 
is unknown and likely a result of a complex interplay between 
genetic susceptibility and environmental factors.
Current treatment of PD is symptomatic and the primary 
pharmacologic therapies include dopamine replacement with 
levodopa, synthetic dopamine agonists, and drugs which 
increase dopamine supply by inhibiting its metabolism 
(catechol-O-methyltransferase inhibitors and monoamine 
oxidase B [MAO-B] inhibitors).
The treatment of PD is symptom-driven and highly indi-
vidualized, depending on each patient’s specific needs. Future 
objectives for the development of new anti-parkinsonian 
medications should include: the prevention of disease pro-
gression, the mitigation or prevention of medication-related 
motor complications, the simplification of treatment regi-
mens, and restorative treatments to provide new neurons or 
stimulate the growth of surviving cells. Recently, novel clini-
cal trial designs have provided a new approach in evaluating 
PD drugs for possible neuroprotective, or disease-modifying, 
effects. The aim of this paper is to review the data on the 
efficacy, safety, and possible disease-modifying effects of 
rasagiline in PD.
MAO-B inhibitors in PD
The interest in MAO-B inhibitors to treat PD stems from 
their ability to slow the breakdown of striatal dopamine. 
Monoamine oxidase (MAO) is an enzyme embedded in 
the outer mitochondrial membrane that is involved in the 
oxidative deamination of monoamine neurotransmitters 
(dopamine, serotonin, norepinephrine) and biogenic amines 
(tyramine).13,14 Two isoforms of the enzyme, MAO-A and 
MAO-B, have been described. MAO-A is located primarily 
in peripheral organs where it contributes ∼80% of total MAO 
activity in the gastrointestinal tract. MAO-B is the major 
isoform in the brain and abundant in the basal ganglia.15,16 
In the human brain the distribution of MAO-A and MAO-B 
differs in various regions. MAO-A is localized to the nor-
adrenergic neurons of the locus coeruleus while MAO-B is 
present in the serotonergic neurons of the raphe nuclei and 
in glial cells.
The propargylamines are selective MAO-B inhibitors 
which have been approved for the treatment of PD. These 
compounds incorporate a propargyl chain which appears to 
confer neuroprotective effects in a variety of in vitro and in in 
vivo model systems.17–21 Selegiline (deprenyl, Eldepryl®) is a 
methylamphetamine with a propargyl residue which selectively 
and irreversibly inhibits MAO. It was approved for treatment of 
PD in the US in 1979. In the DATATOP (Deprenyl and Tocoph-
erol Antioxidative Therapy of Parkinsonism) study, selegiline 
was found to be safe and efficacious in early PD and delayed 
the introduction of levodopa therapy when compared with pla-
cebo.22,23 However, the mild symptomatic effects of selegiline 
confounded the interpretation of a possible neuroprotective 
effect.24 Selegiline is metabolized to L-methamphetamine and 
L-amphetamine, and there has been speculation about possible 
toxic effects of these derivatives.25,26
Rasagiline
Rasagiline (Azilect®; Teva Neuroscience, Inc.) is a second-
generation propargylamine that is a highly selective, irre-
versible MAO-B inhibitor. Rasagiline is a secondary cyclic 
benzylamine and indane derivative. Because it does not 
have an amphetamine-like scaffolding it does not generate 
amphetamine or methamphetamine metabolites. Rasagi-
line is metabolized by cytochrome P-450 to form its chief 
metabolite, 1-(R)aminoindan, which has been shown to have 
neuroprotective effects in vitro.27 Rasagiline is available in 
0.5 mg and 1 mg tablets and is taken once daily.
Rasagiline pharmacology
A number of in vitro and in vivo studies have shown that rasa-
giline has high specificity for the MAO-B isoform. In animal 
models, based on the dose required to inhibit enzyme activity 
by 50% (ED50), rasagiline inhibited MAO-B 60 to 65 times 
more potently than MAO-A.28–30 The specificity of rasagiline 
for MAO-B inhibition was similar to that of selegiline. In a 
small study of 3 healthy individuals administered rasagiline 
1 mg per day for 10 days, positron emission tomography 
using 11C-L-deprenyl tracer showed complete blockade of 
MAO-B binding sites by rasagiline.31
Measurement of the potency of MAO-B of rasagiline 
using ED50 values found it to be ∼5 times more potent than 
selegiline in rats given chronic daily doses. The clinically 
relevant degree of inhibition of MAO-B has been estimated 
to be 80%, and when ED80 values were examined, rasagiline 
exhibited ∼10 times greater potency than selegiline.30Clinical Interventions in Aging 2010:5 151
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In pharmacokinetic studies in healthy volunteers and PD 
patients, rasagiline inhibits MAO-B rapidly and exhibits a 
dose-dependent effect. In a study of single-dose rasagiline in 
healthy subjects, 1, 2, 5, and 10 mg were administered and 
within 1 hour post dose, 33%, 55%, 79%, and 99% platelet 
MAO-B inhibition was achieved, respectively.32 In a study 
of patients with PD, rasagiline had a half-life of 1.34 hours, 
median time to Cmax of 0.5 hours, and volume of distribution 
of 182 L.34
Rasagiline is metabolized via CYP1A2-mediated dealkyl-
ation to 1-R-aminoindan. Mean oral clearance of rasagiline 
is 994.3 L/hour. In subjects with mild hepatic impairment 
(Child–Pugh score of 5–6), caution should be exercised when 
administering rasagiline as the mean peak plasma concentra-
tion and mean area under the curve are increased. Rasagiline 
administration should be avoided in subjects with moderate 
to severe hepatic impairment (Child–Pugh score  7).34
Neuroprotective effects  
of rasagiline
Though the etiopathogenesis of PD is not fully understood, cur-
rent data suggest a role for signal-mediated apoptosis in neuro-
nal cell death in PD and have sparked interest in anti-apoptotic 
agents as possible neuroprotective therapies in PD.35–37 The 
propargylamines have been demonstrated to have anti-apoptotic 
effects in cell culture and animal studies. The anti-apoptotic 
effect appears to be conferred by the propargyl chain and is 
independent of MAO-B inhibition.20,23,38 At the cellular level, 
propargylamines have been shown to exert their neuroprotec-
tive effects by preventing nuclear translocation of GADPH, 
preserving mitochondrial potential, upregulating anti-apoptotic 
molecules, and downregulating pro-apoptotic factors.39
Rasagiline has demonstrated neuroprotective properties 
in a host of in vitro and in vivo studies. In vitro, rasagi-
line protects against an array of toxins, including MPTP, 
  6-hydroxydopamine (6-OHDA) and serum and growth factor 
deprivation (reviewed in38). Rasagiline increased the survival 
of fetal mesencephalic dopaminergic neurons in culture.40 In 
a study using the dopaminergic cell line SH-SY5Y, rasagiline 
protected against N-methyl(R)salsolinol – induced apop-
tosis and was found to stabilize mitochondrial membrane 
potential and induce anti-apoptotic Bcl-2.41 In a rodent PD 
model in which rats were injected with 6-OHDA to produce 
an ipsilateral lesion of the substantia nigra, treatment with 
rasagiline protected dopaminergic neurons and reduced motor 
stereotypies.42 In a rat model of PD which used microinjec-
tions of lactacystin (a ubiquitin-proteosome system inhibitor) 
into the median forebrain bundle, rasagiline was found to 
have  neuroprotective effects.43 A recent study of a transgenic 
mouse model of multiple system atrophy, a neurodegenerative 
Parkinson-plus disease, showed that treatment with rasagiline 
led to significant reduction of 3-NP-induced neuronal loss in 
striatum, substantia nigra pars compacta, cerebellar cortex, 
pontine nuclei and inferior olives.44
The neuroprotective effects of rasagiline appear to extend 
to non-dopaminergic motor neurons as well. Rasagiline 
administration was protective against immediate sequelae 
of closed head injury in the mouse.45 Treatment with rasa-
giline in rats with middle cerebral artery occlusion reduced 
infarct size volume, improved cognitive performance and 
reduced necrotic brain area.46 In a familial mouse model of 
amyotrophic lateral sclerosis rasagiline, in combination with 
riluzole, increased survival time by approximately 20%.47
In comparative studies of rasagiline and selegiline, rasa-
giline demonstrated greater potency as a neuroprotective 
agent.43,48 In addition, a recent study of an animal model 
of PD found that while both rasagiline and selegiline had 
neuroprotective effects, rasagiline also exerted a restorative 
effect on nigrostriatal degeneration.43
Clinical efficacy of rasagiline in PD
Rasagiline as monotherapy in early PD
The pivotal TEMPO trial (Rasagiline Mesylate [TVP-1-12] 
in Early Monotherapy for Parkinson’s Disease Outpatients) 
was a 6-month, randomized, placebo-controlled, double-
blind study to determine the efficacy, safety and tolerability 
of rasagiline in treatment-naïve patients with early PD.49 
A total of 404 subjects with early PD were randomized to 
receive placebo, rasagiline 1 mg/day, or rasagiline 2 mg/day. 
Subjects had to be over age 35 with at least 2 cardinal signs of 
PD and disease severity of Hoehn and Yahr score of III or 
less. Subjects were excluded if they had atypical or second-
ary parkinsonism, a Mini-Mental Status Exam score of 23 
or less, clinically significant depression or unstable medical 
problems. The primary outcome measure was change in the 
total United Parkinson’s Disease Rating Scale (UPDRS) 
score. Secondary outcome measures included change in the 
UPDRS motor subscore, activities of daily living (ADL) 
subscore, and the Beck Depression Inventory score.
At 26 weeks, both the rasagiline 1 mg and 2 mg treatment 
groups had significantly improved motor and total UPDRS 
scores compared with the placebo group (P  0.00001). 
Adjusted total UPDRS score mean change from baseline 
were 4.20 units for the rasagiline 1 mg group and 3.56 units 
for the rasagiline 2 mg group. There were a greater percent-
age of responders (subjects with worsening in UPDRS of Clinical Interventions in Aging 2010:5 152
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less than 3 units) in the treatment groups compared with 
the placebo group (placebo: 49%; rasagiline 1 mg: 66%; 
rasagiline 2 mg: 67%).49
Following the initial 6-month efficacy trial, TEMPO was 
extended to a total period of one year.50 During the second 
phase of the trial, subjects who had been randomized to 
placebo were switched to rasagiline 2 mg/day while subjects 
originally taking rasagiline were continued on their active 
medication. The treatment design was an “add-on” delayed- 
start trial which posited that if treatment with rasagiline had 
a disease-modifying effect rather than a purely symptomatic 
one, the delayed treatment group should not achieve the same 
degree of improvement than the early treatment group (see 
below). The primary measure of efficacy was the change in 
total UPDRS from baseline to week 52.
Three hundred seventy-one subjects from the original 
study entered the second phase. At the end of 52 weeks, the 
mean change in total UPDRS score for the three different 
treatment groups were: 3.01 (rasagiline 1 mg/day); 1.97 
(rasagiline 2 mg/day); 4.17 (delayed rasagiline 2 mg/day). 
Compared with the delayed treatment group, the subjects who 
had been maintained on rasagiline from the outset had smaller 
increases in the total UPDRS score (-0.82 units for rasagiline 
1 mg; -0.29 units for rasagiline 2 mg).50 The results from the 
TEMPO trial suggested a possible disease-modifying effect 
of rasagiline which has been studied further in the ADAGIO 
trial (see below).
Rasagiline as adjunctive treatment in PD
The efficacy of rasagiline as adjunctive therapy in advanced 
PD patients with motor fluctuations was studied in 2 large, 
placebo-controlled trials, LARGO and PRESTO.54,55 The 
PRESTO study (Parkinson’s Rasagiline: Efficacy and 
Safety in the Treatment of “Off”) was a randomized, 
placebo-controlled, double-blind trial of subjects with 
advanced PD with motor fluctuations. The efficacy, toler-
ability and safety of rasagiline as adjunctive therapy were 
determined in 472 PD patients at sites in the US and Canada. 
Eligible patients had to have a Hoehn and Yahr score of less 
than 5 in the “off” state, experience at least 2½ hours in the 
“off “ state daily, and be maintained on an optimal and stable 
dose of levodopa therapy for at least 2 weeks prior to screen-
ing visit. Subjects were randomized to receive rasagiline 
0.5 mg/day, rasagiline 1 mg/day, or matching placebo. The 
primary measure of efficacy was change from baseline in 
mean total daily “off” time; secondary endpoints included 
changes from baseline in the UPDRS-ADL subscale during 
“off” periods, changes in UPDRS-motor subscale during 
“on” times, and the investigators’ clinical global impression 
(CGI-I) of patient improvement. Both rasagiline treatment 
groups demonstrated statistically significant reductions in 
“off ” time compared to placebo. The rasagiline 1 mg/day 
group experienced 0.94 hour less “off ” time than placebo 
and rasagiline 0.5 mg/day had 0.49 hour less “off” time. 
The rasagiline treated groups also demonstrated significant 
improvement on UPDRS-ADL during “off” time, UPDRS-
motor subscore during “on” time, and CGI-I. Daily on-time 
increased during treatment with both doses of rasagiline. 
In patients treated with 1 mg/day of rasagiline, the increase 
in on-time was greater compared with those patients who 
received 0.5 mg/day rasagiline and most of the increase was 
without a secondary increase of dyskinesia. The dyskinesia 
was reported as an adverse event in ∼18% of patients receiv-
ing rasagiline compared with 10% of the placebo group.51
The second study, LARGO (Lasting Effect in Adjunct 
Therapy with Rasagiline Given Once Daily), was an 18-week, 
randomized, placebo-controlled, double-blind, double-
dummy study carried out at 74 sites in Europe, Israel and 
Argentina. The study was designed to test the efficacy and 
safety of rasagiline as an adjunct to levodopa compared with 
placebo and to compare effects of entacapone with placebo. 
Subjects had to have moderate to advanced PD with motor 
fluctuations, have at least 1 hour per day in the “off” state, 
and be clinically stable for at least 14 days prior to baseline. 
687 subjects were randomized to receive rasagiline 1 mg/day, 
entacapone 200 mg with every levodopa dose, or matching 
placebo. The primary endpoint was mean change in daily 
“off” time from baseline. When compared to placebo, 
rasagiline significantly reduced “off ” time (-1.18 hours; 
P = 0.0001) as did entacapone (-1.2 hours; P  0.0001). 
There was a corresponding increase in daily “on” time for 
both treatment groups, most of which was without trouble-
some dyskinesia. There was also a small but significant 
reduction in levodopa dose with rasagiline (∼24 mg/day) 
or entacapone (∼19 mg/day), compared with an increase 
of 5 mg/day with placebo (P = 0.0003. and P = 0.0024 vs 
placebo, respectively). A number of secondary endpoints 
including CGI-score, UPDRS-motor score (“on” state), and 
UPDRS-ADL (“off” state) were significantly improved in 
the rasagiline and entacapone groups.52
Safety and tolerability
In the three phase III clinical trials presented above (TEMPO, 
PRESTO, and LARGO), rasagiline was well tolerated.49–52 
In the first 6 months of the TEMPO study, the frequency 
of adverse events in the treatment and placebo groups was Clinical Interventions in Aging 2010:5 153
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similar. The most commonly reported adverse events were 
infection (18%) and headache (12%). Twenty serious adverse 
events (defined as hospitalizations or new malignancy) 
occurred during the study: 4 in the placebo group, 6 in the 
rasagiline 1 mg group, and 10 in the rasagiline 2 mg group. 
Two subjects in the rasagiline 2 mg group developed skin 
cancer (melanoma and squamous cell carcinoma).49 During 
the second phase of the TEMPO study (when all participants 
were receiving rasagiline), the most commonly reported side 
effects were: infection (10.8%), headache (5.4%), uninten-
tional injury (4.9%), and dizziness (4.6%). Serious adverse 
events included 17 hospitalizations and 5 newly diagnosed 
neoplasms including melanoma (1), basal cell carcinoma (1), 
and squamous cell carcinoma (2).50 In the long-term exten-
sion of the TEMPO study, the most common adverse events 
(AEs) reported were infection, accidental injury, dizziness, 
sleep disorder, and nausea.53 In the PRESTO trial, subjects 
taking rasagiline reported more weight loss, vomiting, 
anorexia, dyskinesia and balance difficulty when compared 
with the placebo group. The gastrointestinal adverse reac-
tions appeared to be dose-dependent. Rasagiline did not 
have any adverse effects on blood pressure or pulse. Three 
cases of melanoma developed in the rasagiline group during 
the study.51 In the LARGO study, the active treatment and 
placebo groups had similar frequency of adverse events. The 
occurrence of dopaminergic adverse events was similar in all 
three groups. Postural hypotension occurred in 2% of subjects 
in the rasagiline and entacapone groups.52
Treatment discontinuation rates were low in all three 
  studies. In the TEMPO trial, there was no statistically signifi-
cant difference between early discontinuation in the rasagiline 
and placebo groups.49 Termination due to AE observed in the 
open-label extension of the TEMPO trial was similar in the 
delayed-start and early start groups (11.4% vs 10.5%).53 In 
the LARGO study, there were fewer early discontinuation 
rates and fewer discontinuations due to adverse events in the 
rasagiline group compared with entacapone and placebo.52
Serotonergic drugs
The development of serotonin syndrome, characterized by 
acute changes in mental status, autonomic dysfunction, 
myoclonus and hyperreflexia, has been described when 
nonselective MAOIs and selective serotonin reuptake inhibi-
tors (SSRIs) are taken together. The possibility of serotonin 
syndrome occurring with concomitant use of MAO-B inhibi-
tors and SSRIs has been suggested54 though reported cases 
appear to be rare. In a survey of investigators in the Parkinson 
Study Group, a possible serotonin syndrome was reported in 
11 of 4568 patients (0.24%) taking both selegiline and SSRI. 
Only 2 patients experienced serious symptoms (0.04%) and 
no deaths were reported.55
In both the TEMPO and LARGO studies, a limited 
number of antidepressants including SSRIs were permitted: 
sertraline, paroxetine, citalopram, trazodone and amitripty-
line. No adverse interactions were reported.49,52 In the Azilect 
post-marketing period, non-fatal cases of serotonin syndrome 
have been reported in subjects taking antidepressants and 
rasagiline concomitantly. Current Azilect labeling advises 
the avoidance of coadministration of rasagiline and antide-
pressants.34 In practice, this may be difficult given the high 
prevalence of depression in PD. Therefore, clinical judgment 
and vigilance should be used when treating PD patients with 
both rasagiline and an antidepressant, and patients should be 
educated about possible drug interactions and the symptoms 
associated with serotonin syndrome.
Tyramine and rasagiline
Tyramine, an indirectly acting sympathomimetic found in 
aged cheeses and cured meats, is metabolized by MAO in the 
gastrointestinal system. A “cheese effect”, tyramine pressor 
response, can occur in patients taking non-selective MAOIs 
(ie, tranylcypromine, phenelzine) who ingest foods high in 
tyramine.56 Because the vast majority of MAO in the intestine 
is the MAO-A isoform, a selective MAO-B inhibitor such 
as rasagiline is not likely to cause this effect. However, such 
selectivity diminishes with increasing dose and because of 
this concern, the US Food and Drug Administration initially 
required a warning to restrict dietary tyramine in patients 
taking rasagiline. In the three phase III studies of rasagiline 
in PD (TEMPO, PRESTO, LARGO), there were no specified 
dietary restrictions and rasagiline was well-tolerated with no 
reported tyramine pressor reactions.49–55
In a study of PD patients enrolled in the TEMPO or 
PRESTO trials, tyramine challenges of 50 to 75 mg were 
performed on 72 rasagiline-treated patients and 38 placebo-
treated patients immediately following the completion of 
each study, within 24 hours after the last rasagiline dose. 
None of the 55 subjects from the TEMPO study (38 rasa-
giline, 17 placebo) met the prespecified endpoint (three 
consecutive measurements of SBP with increases of more 
or equal with 30 mm Hg or heart rate reduction less then 
40 bpm over 10 min). In the PRESTO study, 3/34 patients 
taking rasagiline and 1/21 patients taking placebo developed 
asymptomatic, self-limiting elevation in SBP  30 mm Hg 
for 3 consecutive measurements after tyramine challenge, 
but without bradycardia or ECG changes.57Clinical Interventions in Aging 2010:5 154
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A recent study conducted in healthy subjects assessed 
tyramine sensitivity when administered with rasagiline. 
There were seven treatment groups and within each group 
subjects were randomly assigned to receive MAO-I or pla-
cebo. MAO-Is tested were: phenelzine 45 mg/day, selegiline 
10 mg/day, and increasing doses of rasagiline ranging from 
1 mg/day to 6 mg/day. The primary outcome measure was 
the ratio of the amount of tyramine needed to drive a spe-
cific elevation of blood pressure off drug vs on drug. The 
ratio was highest for phenelzine. Difference in outcome 
for rasagiline vs placebo and selegiline was not significant, 
indicating that rasagiline at recommended doses was a selec-
tive MAO-B inhibitor and as selective as selegiline.58 The 
results of this study were recently reviewed by the FDA and 
the bolded warning for tyramine was removed.34
Other drug interactions
Rasagiline is a substrate for CYP1A2 enzyme and therefore 
patients who are taking CYP1A2 inhibiting drugs should 
receive a maximum dose of rasagiline 0.5 mg daily.
Concomitant use of meperidine, tramadol, methadone, 
propoxyphene, dextromethorphan and St. John’s wort is 
contraindicated. There is no contraindication for use of 
rasagiline with sympathomimetic agents or general or local 
anesthetics.
Potential disease-modifying effects 
of rasagiline in PD
A current goal of PD research is the identification of neu-
roprotective, or disease-modifying, agents. A number of 
promising candidate drugs have been tested but results have 
been limited or confounded by lack of reliable biomarkers of 
disease progression and potential symptomatic drug effects.59 
As discussed earlier, rasagiline has been shown to provide 
neuroprotective effects in in vitro and in vivo studies. The 
TEMPO results suggested a potential disease-modifying 
effect of rasagiline and an open-label extension study of the 
TEMPO trial demonstrated that the beneficial effect of early 
rasagiline treatment persisted for up to 6.5 years.53 The ADA-
GIO (Attenuation of Disease Progression with Azilect Given 
Once-daily) study was designed to further study the potential 
of rasagiline as a neuroprotective, or disease-modifying, 
agent. ADAGIO was the first prospectively designed, mul-
ticenter, placebo-controlled, double-blind trial utilizing a 
delayed-start method to study rasagiline in early untreated PD 
patients. The delayed-start design was employed to attempt 
to avoid confounding symptomatic medication effects seen 
in previous trial designs. In this paradigm, there are two 
phases. In the first phase, drug-naïve patients are random-
ized to receive active treatment or placebo for a fixed time 
interval. In the second phase, patients taking the placebo drug 
are switched to the study drug so that patients in all study 
groups are receiving active treatment. If the study drug has 
symptomatic effects only, it would be expected that any dif-
ferences between the two groups that developed in the first 
phase would not persist in the second phase. However, if there 
were disease-modifying as well as symptomatic effects of the 
active treatment, differences between the two groups should 
persist at the end of the second phase, ie, the delayed-start 
group would not “catch up” to the early-start group.60
ADAGIO was an 18-month long study performed in 
2 phases, each lasting 36 weeks. 1176 subjects were ran-
domized to 4 different treatment groups: 1) placebo dur-
ing phase I followed by 1 mg/day rasagiline in phase II; 2) 
placebo during phase I followed by 2 mg/day rasagiline in 
phase II; 3) 1 mg/day rasagiline during phases I and II; 4) 
1 mg/day rasagiline during phases I and II. There were three 
primary efficacy endpoints: 1) rate of UPDRS progression 
during the placebo-controlled phase from week 12 to week 
36 for the placebo and rasagiline treated groups, 2) estimate 
of change from baseline to week 72 in total UPDRS score in 
both groups, and 3) non-inferiority of the slope estimates of 
the early-start and delayed-start rasagiline groups during the 
active phase (weeks 48–72). Rasagiline at a dose of 1 mg/day 
met all three hierarchical primary endpoints: slower rate of 
worsening as measured by change in the slopes in the first 
phase (0.09 ± 0.02 vs 0.14 ± 0.01 points per week; P = 0.01); 
less worsening in mean total UPDRS between baseline and 
week 72 (2.82 ± 0.53 vs 4.50 ± 0.56 points; P = 0.02); nonin-
feriority of the slopes in the active phase (0.85 ± 0.02 vs 0.85 ± 
0.02 points per week; P  0.0001). Rasagiline 2 mg dose, 
however, did not reach all three endpoints of the primary 
analysis. A subgroup analysis of the 2 mg group showed that 
for those subjects with the highest quartile of UPDRS scores 
at baseline (patients more affected by the disease), early-start 
rasagiline provided significant benefit over delayed-start rasa-
giline. These results suggest that the higher dose of rasagiline 
may have masked a possible disease-modifying effect in PD 
subjects with milder disease.61
The different results for the two doses of rasagiline are 
difficult to explain. In addition, the clinical significance of a 
1.7 unit difference on the UPDRS is not clear. Future studies 
are needed to confirm the positive findings for rasagiline 
1 mg, and studies of rasagiline PD patients with more 
advanced disease should be considered to untangle symp-
tomatic from potential disease-modifying effects of higher Clinical Interventions in Aging 2010:5 155
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dose rasagiline. Moreover, long-term data will be needed to 
determine whether the benefits seen with early-start rasagiline 
1 mg persist with disease progression.
Conclusions
Rasagiline is a potent, selective and irreversible MAO-B 
inhibitor that has demonstrated efficacy in early and advanced 
stages of PD. Rasagiline possesses a number of advantages 
over selegiline including its once daily dosing, milder side 
effect profile, more potent MAO-B inhibition, and non-
amphetamine metabolites. Rasagiline has also been shown 
to have neuroprotective properties in cell culture and ani-
mal models of PD. The ADAGIO trial has suggested that 
rasagiline 1 mg/day may have a disease-modifying effect in 
early PD. However, these findings were not borne out with 
the 2 mg dose. Further studies are needed to confirm these 
results and to determine whether initial benefits with rasa-
giline are sustained and have long-term effects on disease 
progression in PD.
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